title: Thrice-daily biphasic insulin aspart 30 may be another therapeutic option for Chinese patients with type 2 diabetes inadequately controlled with oral antidiabetic agents.
authors.affiliation: Department of Endocrinology, China-Japan Friendship Hospital, Beijing, China. yangwenying1707@yahoo.com.cn
authors.forename: Wen-ying
authors.initials: WY
authors.lastname: Yang
authors.forename: Qiu-he
authors.initials: QH
authors.lastname: Ji
authors.forename: Da-long
authors.initials: DL
authors.lastname: Zhu
authors.forename: Jin-kui
authors.initials: JK
authors.lastname: Yang
authors.forename: Lu-lu
authors.initials: LL
authors.lastname: Chen
authors.forename: Zhi-min
authors.initials: ZM
authors.lastname: Liu
authors.forename: De-min
authors.initials: DM
authors.lastname: Yu
authors.forename: Li
authors.initials: L
authors.lastname: Yan
mesh_terms: D061265:Biphasic Insulins; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007328:Insulin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D061267:Insulin Aspart; D007336:Insulin, Isophane; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D061265:Biphasic Insulins; D007004:Hypoglycemic Agents; D007328:Insulin; C557564:insulin aspart, insulin aspart protamine drug combination 30:70; D007336:Insulin, Isophane; D061267:Insulin Aspart